

NOVADEL PHARMA INC  
Form 8-K  
February 14, 2005

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) February 9, 2005**

---

**NOVADEL PHARMA INC.**  
**(Exact Name of Registrant as Specified in Its Charter)**

---

**Delaware  
(State or other  
jurisdiction  
of incorporation)**

**001-32177**  
**(Commission File No.)**

**22-2407152**  
**(I.R.S. Employer  
Identification No.)**

**25 Minneakoning Road**  
**Flemington, New Jersey 08822**  
**(Address of principal executive offices) (Zip Code)**

**(908) 782-3431**  
**(Registrant's telephone number, including area code)**

**N/A**  
**(Former name or former address, if changed since last report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events**

On February 9, 2005, NovaDel Pharma Inc. (the “Company”), issued a press release to announce that it has initiated a pilot pharmacokinetic study in humans of its lingual spray formulation of ondansetron, the largest selling anti-emetic agent, currently marketed in the United States as Zofran® by GlaxoSmithKline. The full text of the press release is set forth in Exhibit 99.1 hereto.

On February 14, 2005, the Company, issued a press release to announce positive results of a pilot pharmacokinetic study that was conducted using its lingual spray version of zolpidem tartrate (the active ingredient marketed under the brand name Ambien® by Sanofi-Aventis). The full text of the press release is set forth in Exhibit 99.2 hereto.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1. Press release dated February 9, 2005, titled “NovaDel Initiates Pilot Clinical Study of Lingual Spray Version of World’s Leading Anti-Emetic.”

99.2. Press release dated February 14, 2005, titled “NovaDel Releases Positive Results of Pilot Pharmacokinetic Study of Zolpidem Tartrate.”

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Jean W. Frydman

---

Name: Jean W. Frydman  
Title: Vice President and General Counsel

Date: February 14, 2005

**EXHIBIT INDEX**

**Exhibit Description**

- 99.1 Press release dated February 9, 2005, titled “NovaDel Initiates Pilot Clinical Study of Lingual Spray version of World’s Leading Anti-Emetic.”
- 99.2 Press release dated February 14, 2005, titled “NovaDel Releases Positive Results of Pilot Pharmacokinetic Study of Zolpidem Tartrate.”